The European Medicines Agency approved Eli Lilly’s anti-migraine drug Emgality (galcanezumab) as a treatment for patients who have at least four migraine days per month.
The drug works by blocking the release of calcitonin gene-related peptide (CGRP). The FDA approved Emgality in September.
Amgen’s Aimovig (erenumab) and Teva’s Ajovy (fremanezumab) were previously approved as treatments for migraine.
